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Anticoagulants are commonly used drugs that are frequently encountered during device placement.
Deciding when to halt or continue the use of anticoagulants is a balance between the risks of throm-
boembolism versus bleeding. Patients taking warfarin with a high risk of thromboembolism should
continue to take their warfarin without interruption during device placement while ensuring their
international normalized ratio remains below 3. For patients who are taking warfarin and have low risk
of thromboembolism, either interrupted or continued warfarin may be used, with no evidence to clearly
support either strategy. There is little evidence to support continuing direct acting oral anticoagulants
(DOACs) for device implantation. The timing of halting these medications depends largely on renal
function. If bleeding occurs, warfarin's anticoagulation effect is reversible with vitamin K and activated
prothrombin complex concentrate. There are no DOAC reversal agents currently available, but some are
under development. Regarding antiplatelet agents, aspirin alone can be safely continued while clopi-
dogrel alone may also be continued, but with a slightly higher bleeding risk. Dual antiplatelet therapy for
bare-metal stent/drug-eluting stent implanted within 4 weeks/6 months, respectively, should be con-
tinued due to high risk of stent thrombosis; however, if they are implanted after this period, then clo-
pidogrel can be halted 5 days before the procedure and resumed soon after, while aspirin is continued. If
the patient is taking both aspirin and warfarin, aspirin should be halted 5 days prior to the procedure,
while warfarin is continued.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia
managed in clinical practice and the most common arrhythmia
requiring hospitalization [1,2]. Thromboembolism occurs with
similar incidence, regardless of the form of AF [3,4]. AF manage-
ment includes anticoagulation to prevent thromboembolic stroke,
its most debilitating complication [2,5]. Anticoagulation with
warfarin, at a target international normalized ratio (INR), or with a
direct acting oral anticoagulant (DOAC), has consistently been
shown to reduce the risk of stroke and is therefore a major goal of
therapy for AF [6,7]. AF is the most common reason for antic-
oagulation [8]. Anticoagulants are also frequently used for other
indications, ranging from venous thromboembolism to mechanical
prosthetic heart valves [9]. Indeed, their widespread use in clinical
practice leads to a high likelihood of their being encountered in
patients undergoing invasive procedures. Cardiac implantable
electrophysiological device (CIED) surgeries, which include pace-
maker (PM) and implantable cardioverter deﬁbrillator (ICD) pla-
cements, are now commonplace worldwide with approximately
1.5 million procedures performed per year. Of patients who
undergo such procedures, up to 35% require long-term antic-
oagulation [10].
When determining who should receive anticoagulation, a risk-
stratiﬁcation model is used. The rationale behind risk stratiﬁcation
is that although anticoagulation has clearly been shown to be
more effective than antiplatelet agents or placebos in the pre-
vention of thromboembolic stroke, their use should be restricted
to patients whose risk for a thromboembolic event exceeds their
risk of hemorrhage [11–13]. Risk factors for thromboembolic
events in nonvalvular AF include a history of stroke, diabetes
mellitus, hypertension, heart failure, and age. These were incor-
porated into the initial score called CHADS2 [6,14]. The annual risk
of stroke increased incrementally from 2%, with a score of 0, to as
high as 22%, with a score of 6, in the absence of anticoagulant
therapy [11,15,16]. A second score known as CHA2DS2-VASc was
developed to further delineate the risk in the perceived low-risk
groups using additional risk factors [6,17,18].
The risk of bleeding also increases substantially with the use of
anticoagulants, and this presents a challenge to their clinical use
[6,19]. A problem that arises is how to manage patients on antic-
oagulation treatment who require an invasive procedure that
inherently increases their risk of bleeding. In this review, we will
discuss the management of antithrombotic therapy in patients
undergoing CIED surgery, including anticoagulants, such as war-
farin and the DOACs, and antiplatelet drugs, such as aspirin and
clopidogrel.2. Oral anticoagulants
Warfarin has been the main oral anticoagulant used in clinical
practice for nearly ﬁfty years, especially in patients with AF. It
inactivates vitamin K in the hepatic microsomes by inhibiting
epoxide reductase, which hinders the formation of clotting factors
that are dependent on vitamin K, such as factors II (prothrombin),
VII, IX, and X [20]. The onset of the therapeutic action of warfarin is
delayed by two to seven days while the preformed factors are
depleted. Warfarin dosing is targeted to a therapeutic INR, which is
usually 2–3 in AF but may be higher for mechanical mitral valves
[20,21]. It has few side effects other than its major and most sig-
niﬁcant side effect, which is bleeding [22]. In addition, the INR
requires monitoring in order to maintain it in a therapeutic range.
Numerous medications interact with warfarin and affect its meta-
bolism [20]. Over-anticoagulation leads to a signiﬁcant risk of
bleeding when the INR is greater than 3 [23,24]. While there is atrend away from warfarin treatment towards use of the newer
anticoagulants, most clinicians maintain warfarin treatment in
patients who are already taking the drug and have a stable INR [13].
DOACs are drugs that directly inhibit either thrombin or acti-
vated factor X and were designed in response to the need for an
oral anticoagulant that did not require frequent monitoring and
was less likely to have dietary and medication interactions. Three
drugs gained approval in rapid succession: dabigatran etexilate,
rivaroxaban, and apixaban [12]. A fourth followed soon after:
edoxaban [25,26] (awaiting approval in Canada). All four are oral
medications that do not require anticoagulation monitoring via
blood tests. All four DOACs have rapid time to peak plasma con-
centrations of 2 (rivaroxaban/edoxaban) to 6 h (dabigatran);
therefore, immediately after the ﬁrst dose, patients are well
anticoagulated [27]. The ﬁrst of these drugs, dabigatran, is a potent
direct competitive inhibitor of thrombin. The RE-LY trial demon-
strated that dabigatran was comparable to warfarin in terms of
stroke prevention with lesser rates of major hemorrhage in the
110 mg group, and superior to warfarin with equal rates of
hemorrhage in the 150 mg group [28]. Rivaroxaban is an oral,
direct factor Xa inhibitor and was shown in the ROCKET-AF trial to
be similar to warfarin for the prevention of stroke in nonvalvular
AF with no signiﬁcant difference in the risk of major bleeding [29].
Rivaroxaban is used at a dose of 20 mg once daily or 15 mg daily if
the creatinine clearance (CrCl) is between 30 and 49 mL/min.
Apixaban, also an oral direct factor Xa inhibitor, was demonstrated
to be superior to warfarin in preventing stroke or systemic
embolism in nonvalvular AF in the ARISTOTLE trial [30]. The dose
of apixaban is 5 mg twice daily with a dose reduction to 2.5 mg
twice daily if two of the following three conditions are present:
age 80 years or older, body weight of 60 kg or less, and a serum
creatinine level of 133 mmol/L or greater [27,30]. Edoxaban is
another oral direct factor Xa inhibitor that was shown to be
noninferior to warfarin with respect to the prevention of stroke or
systemic embolism in nonvalvular AF and was associated with
signiﬁcantly lower rates of bleeding in the ENGAGE AF-TIMI 48
trial [31]. The recommended dose of edoxaban is 60 mg once daily
with a reduced dose of 30 mg once daily if CrCl is between 15 and
50 mL/min [32]. DOACs may be useful for use in elderly patients
on a multitude of medications that may interact with warfarin;
indeed, DOACs have been shown to be safe in the elderly [33].3. Management of warfarin during pacemaker/implantable
cardioverter deﬁbrillator insertion
Until recently, warfarin use was halted before PM/ICD insertion
and the patient was bridged with intravenous (IV) unfractionated
heparin or subcutaneous low-molecular-weight heparin (LMWH) if
the thromboembolic risk was considered high (usually CHADS2
Z3) [34–36]. This was usually performed by discontinuing warfarin
use ﬁve days before the procedure and initiating IV heparin or
LMWH 3 days before the procedure, once the INR decreased below
2; the procedure was usually performed when the INR was less
than 1.5 and after halting IV heparin 4 h prior to the procedure or
after halting the last dose of LMWH 24 h prior [36]. This process is
marred by several difﬁculties and logistical issues. To start IV
heparin, the patient must be a hospital inpatient for several days
before the procedure. In addition, heparin requires frequent
checking of the PTT with dose adjustments to ensure a therapeutic
time; LMWH is less problematic in terms of monitoring, but still
requires daily injections and CrCl above 30 mL/min [34]. Some-
times, the INR does not decrease below 1.5 on the day of the pro-
cedure, leading to the administration of vitamin K to decrease the
INR, which results in restoring the INR to the therapeutic range after
post-procedural reinitiation of warfarin and a further increase in
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egy leads to signiﬁcantly increased rate of device-pocket hema-
toma, ranging from 17% to 31% [37]. A recent systematic review
demonstrated that compared to no heparin, heparin bridging was
associated with a combined odds ratio of 4.47 for the development
of pocket hematoma and prolonged hospital stay [38]. The con-
sequence of a device-pocket hematoma is substantial, including the
need for a prolonged period of time off anticoagulation with a risk
of thromboembolism, the need for further procedures to clear the
hematoma, an increased risk of infection, and an increase in hos-
pital stay; when a hematoma occurs, the increased risk of infection
can be as much as 22-fold higher, as demonstrated in the REPLACE
registry [39].
A major change has recently occurred in the management of
warfarin during pacemaker insertion because of the results of the
large trial, BRUISE CONTROL, in which 661 patients with an annual
thromboembolism risk greater than 5% per year (CHADS2Z3)
were randomized to continued warfarin therapy versus bridging
therapy during elective pacemaker/ICD implantation [10]. The trial
was performed after several case series and smaller trials had
shown a beneﬁt to continued warfarin therapy and several centers
had shifted their clinical practice to continued warfarin therapy; a
meta-analysis of these trials showed a beneﬁt of continued oral
anticoagulation versus bridging in terms of reduced device-pocket
hematoma and hematoma drainage/revision [37]. The aforemen-
tioned bridging strategy was used in this trial. The trial was
stopped early because the results showing 16% of the bridging
group to have clinically signiﬁcant hematoma versus just 3.5% of
the continued warfarin group [10]. Furthermore, there was sig-
niﬁcantly more hematoma causing prolonged hospitalization,
hematoma requiring interruption of anticoagulation and hema-
toma requiring an evacuation [10]. This study represents the main
body of evidence for switching to a continued warfarin strategy in
those at higher risk of thromboembolism. An algorithm for the
peri-procedural management of warfarin is shown in Fig. 1. To
provide evidence on whether a bridging strategy is beneﬁcial in
high risk patients, the recent BRIDGE study randomized 1884
patients to bridging with initiation of low-molecular-weight
heparin three days before the procedure versus no bridging. The
study showed an incidence of arterial thromboembolism of 0.4% in
the no-bridging group versus 0.3% in the bridging group (95%
conﬁdence interval [CI], 0.6 to 0.8; P¼0.01 for noninferiority),
while the incidence of major bleeding was 1.3% in the no-bridging
group and 3.2% in the bridging group (relative risk, 0.41; 95% CI,
0.20–0.78; P¼0.005 for superiority) [40]. Several additional stu-
dies have shown an increased risk of bleeding with bridgingFig. 1. Peri-device surgery warfarin management [30,39,58]. Low risk for thromboembo
CHA2DS2-VASc score of r2. High risk for thromboembolism (annual risk of thromboem
CHA2DS2-VASc of 2 due to stroke or TIA within 3 months, patients planned for cardiover
prosthetic mitral valve, caged ball or tilting disc aortic valve, a combination of bileaﬂet ao
thromboembolism (within 3 months) or an intra-cardiac thrombus.[35,36]. Indeed, a recent meta-analysis showed that compared
with heparin bridge, continued oral anticoagulation at the time of
CIED surgery was associated with a signiﬁcantly lower risk of
postoperative bleeding (OR¼0.25, 95% CI 0.17–0.36, Po0.0000),
but there was no difference noted in the risk of thromboembolic
events between the 2 strategies (OR¼1.86, 95% CI 0.29–12.17,
P¼0.57) [41]. In addition, continued warfarin therapy is much
more cost effective than bridging therapy [42]. When performing
device surgery without interruption of warfarin, the INR should be
checked 3–7 days prior to the procedure to provide time for dose
adjustment, and then once more on the day of the procedure. The
INR on the day of the procedure should be less than or equal to the
upper limit of the therapeutic range prescribed for the patient,
usually r3 (r3.5 for some prosthetic heart valves) [25].
Regarding patients with a lower annual risk of thromboem-
bolism (o5%), there is no clear evidence for continued warfarin
versus discontinuing warfarin. Clearly, a bridging strategy should
not be used, given the low risk of thromboembolism and higher
risk of device-pocket hematoma with bridging. Current guidelines
suggest to stop warfarin treatment 3–4 days before the procedure,
to perform the procedure once the INR is o1.8, and resume
warfarin 12–24 h later [25,34]. However, as suggested in a recent
guideline and in keeping with evidence from two recent meta-
analyses, continued warfarin use may be considered, especially if
the patient has a history of previous transient ischemic attack or
embolic stroke [25].4. Management of direct acting oral anticoagulants during
pacemaker insertion
There are less data available regarding management of DOACs
peri-procedurally. The general principle is that PM/ICD implanta-
tion is considered a low bleeding risk procedure [10,34]. Because
of the predictable waning anticoagulant effects of DOACs, bridging
therapy is not required and management involves timing the
cessation and re-initiation of the drug based on the predicted
clearance, which takes renal function into account [27,43]. A
recent Canadian study showed that device implantation per-
formed with DOAC interruption, but without bridging [44]. In
patients with normal renal function undergoing a low bleeding
risk procedure, the usual practice is to discontinue the DOAC 24 h
(i.e. last dose 2 days before) prior to the procedure and to reinstate
the drug 24–48 h after, provided no signiﬁcant bleeding has
occurred [25,34,45] (Fig. 2). A large randomized control trial
(BRUISECONTROL2: ClinicalTrials.gov NCT01675076) is underway,lism (annual risk of thromboembolic events o5%) includes patients with AF and a
bolic events 4¼5%) includes patients with AF and a CHA2DS2-VASc score of Z3, a
sion or deﬁbrillation testing at device implantation, AF and rheumatic valve disease
rtic valve prosthesis with atrial ﬁbrillation and a CHA2DS2-VASc of 2, recent venous
Fig. 2. Peri-device surgery DOAC management [39,42]. A strategy of continued DOAC for patients at high risk of arterial thromboembolism is currently under investigation
[43] .* Based on pharmacokinetics but no recommendation in guidelines if CrCl o80.
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continuing DOACs—its results are eagerly awaited [46]. The details
for each separate DOAC are discussed below.
Dabigatran is a twice daily drug with a half-life of 14 h, if the
CrCl is above 50 mL/min. Its use should be halted the day before
surgery, which translates to missing 2 doses before the day of
surgery. This usually results in a 12–25% residual anticoagulant
effect at the time of surgery, which is acceptable given the low risk
of bleeding [25,27,45]. If the CrCl is between 30 and 50 mL/min,
signifying moderate renal impairment and a likely half-life of 15–
18 h, then dabigatran use should be halted 2 days before surgery,
i.e., 4 missed doses to give the same residual anticoagulant effect.
Dabigatran should not be used in patients with a CrCl of less than
30 mL/min. The drug should then be resumed 24 h postoperatively
[25,34,45,47,48]. An observational study showed that continued
dabigatran treatment did not result in increased bleeding; only
one episode of minor bleeding occurred and that was in a patient
on dual antiplatelet therapy [49]. This ﬁnding has been replicated
in other studies [50]; thus, the results of the randomized control
trial [46] are awaited before ﬁnal recommendations can be made
regarding continuation of DOACs.
Rivaroxaban is a once daily drug with a half-life of 9 h if the
CrCl is above 30 mL/min. Its use should halted the day before
surgery, which translates to missing one dose before the day of
surgery and results in a 12–25% residual anticoagulant effect at the
time of surgery, which is acceptable given the low risk of bleeding
[27,47,48]. Again, rivaroxaban should not be used in patients with
a CrCl less than 30 mL/min, but if used in patients with a CrCl
between 15 and 30 mL/min, at least 36 h of drug interruption is
advised [25]. Use of the drug should then be resumed 24–48 h
postoperatively [34,45]. Apixaban is similar to rivaroxaban in its
mechanism of action and half-life of 9 h if CrCl is above 30 mL/min
[27,45]. Therefore, use of the drug may be halted the day before
surgery and resumed 24–48 h postoperatively, if renal function is
430 mL/min [34,45,47,48]. If apixaban is used in patients with a
CrCl between 15 and 30 mL/min then at least 36 h of drug inter-
ruption is advised [25]. Edoxaban is a once daily drug with a half-
life of 10–14 h if the CrCl is above 30 mL/min [32]. However, there
is less guidance available regarding edoxaban and the current
recommendation is for use of the drug to be halted the day before
surgery and resumed 24–48 h postoperatively, if renal function is
480 mL/min [25,32]. Given the pharmacokinetics of edoxaban,these recommendations will most likely extend to a CrCl of greater
than 30, but guidance is currently lacking.5. Anticoagulation reversal
Anticoagulation may require elective (as described above) or
emergent reversal. Vitamin K may be administered, which sub-
stantially reduces INR within 24 h; the rapidity of INR decrease
depends on the route of administration and the dose [51,52]. Oral
administration is preferred if there is no need for very rapid
reversal because it is effective, safe, convenient, and predictable
[52,53]. Doses required may range from 1 mg to 10 mg, keeping in
mind that although the INR will decrease faster and to lower levels
with higher doses, returning to therapeutic INR will be delayed
and more difﬁcult due to warfarin resistance, which may last up to
a week [51,52]. Intravenous administration is the fastest route and
lowers the INR within 12 h. If rapid reversal is required, then this is
easily achieved using prothrombin complex concentrate (PCC),
which is the current preferred method of rapid reversal of war-
farin and its use is preferable to fresh frozen plasma [52].
To date, there is no reversal agent for DOACs, although they are
currently in development and may soon be available for clinical
use [54]. First, administration of the drug should be halted and an
investigation into the cause of bleeding carried out with treatment
if indicated [55]. Neither vitamin K, fresh frozen plasma, nor
prothrombin complex concentrate fully reverse the anticoagulant
effects of DOACs, but they are used in clinical practice because of
the lack of an alternative [27]. Dabigatran may be cleared relatively
efﬁciently by dialysis [56]. Despite the absence of reversal agents,
in comparative studies DOACS (except dabigatran at the higher
dose) had lesser rates of bleeding than did warfarin [28–30]. In
addition, DOACs are cleared reliably and quickly, and by the time a
bleed occurs, their levels may already be waning [27]. There are
several blood tests that when positive indicate the presence of
DOACs in the blood and when normal do not infer their absence.
For dabigatran, the thrombin time is a very sensitive indicator of
the drug's presence in the blood. In addition, the PTT may be
prolonged if dabigatran is present. For rivaroxaban, a prolonged
PT/INR may indicate the presence of the drug. Currently, there is
no reliable method to detect the presence of apixaban or edoxaban
in coagulation studies. Anti-Xa levels may be used to detect the
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in the blood [55]. Non-speciﬁc blood thinners, such as DDAVP and
tranexamic acid, should be used because even though their efﬁ-
cacy is not proven, they cause little harm and may add beneﬁt [57].
Reversal agents the focus of ongoing trials that show promise, and
they may soon be available in clinical practice. Idarucizumab is a
speciﬁc reversal agent for dabigatran and a recent phase III trial
showed rapid and durable complete reversal [58]. Andexanet
alpha is a reversal agent for factor Xa inhibitors, such as apixaban,
rivaroxaban, or edoxaban, and phase two studies of this compound
have also shown rapid complete reversal [59]. Aripazine is a
reversal agent that targets all DOACs and has shown complete
reversal [54].6. Management of antiplatelet drugs during pacemaker/
implantable cardioverter deﬁbrillator insertion
Antiplatelet drugs are commonly used in patients who require
PM/ICD insertion. Aspirin and clopidogrel are the most widely
used antiplatelet drugs. A study by Tomkins et al. in patients who
underwent CIED surgery showed that the risk of developing a
pocket hematoma doubled when using aspirin alone, as compared
to no antiplatelet medication, and was four-fold higher when
comparing dual antiplatelet therapy (DAPT) to no antiplatelet [60].
A smaller study showed that approximately 18% of patients on
clopidogrel developed a hematoma after PM/ICD insertion, but
none of those who had clopidogrel treatment halted held for
4 days or more developed a hematoma. The risk further increased
if aspirin and clopidogrel treatment were combined. Other studies
have shown that clopidogrel is associated with a hematoma for-
mation rate of 25%, compared to just 4% when its use is dis-
continued prior to the procedure. In addition, there was no sig-
niﬁcant difference in hematoma formation if aspirin was con-
tinued or discontinued [37]. The main necessity for dual-
antiplatelet therapy arises post-insertion of coronary stents to
decrease the risk of stent thrombosis and after acute coronary
syndrome. The PARIS study was a two-year prospective observa-
tional study that enrolled 5018 patients to examine the effect of
DAPT cessation after PCI on major adverse cardiovascular events
(MACE), which is a composite of cardiac death, deﬁnite or prob-
able stent thrombosis, myocardial infarction, or target-lesion
revascularization. The results of this study demonstrated that
30-days, post-stent insertion, DAPT could be safely interrupted and
reinitiated 14 days post procedure with no increase in MACE,Fig. 3. Peri-device surgery manaincluding no increase in stent thrombosis [61]. However, there is
still no clear consensus regarding DAPT management. An easy-to-
use summary is as follows (Fig. 3): if the patient is only taking
aspirin, then aspirin can be safely continued. If the patient is only
on clopidogrel, then continue clopidogrel. For patients on DAPT,
though the Paris study demonstrated that DAPT can be safely
interrupted after 30 days, more evidence would be needed in the
form of a randomized controlled trial before such a recommen-
dation can be made. Given current evidence, the following is
recommended: continue DAPT if a bare-metal stent (BMS) was
inserted in the last 4 weeks and if a drug-eluting stent (DES) was
implanted in the last 6 months. If more than 4 weeks/6 months
have elapsed after BMS/DES implantation, respectively, then clo-
pidogrel can be halted 5–7 days prior to the procedure and
resumed as soon as possible after, while continuing aspirin
[25,61,62]. Current guidelines also suggest deferring elective
device implantation, if possible, until the completion of DAPT.
Recommendations from recent guidelines are summarized in
Table 1. There is no reliable way to reverse the effects of anti-
platelet medications, other than administering platelet transfu-
sions, and the efﬁcacy of this approach remains under debate [63].7. Conclusion
Antithrombotic therapy and its peri-procedural management
continue to be a rapidly evolving area. There is now clear evidence
that continuing warfarin treatment during CIED surgery insertion
is safe, without a signiﬁcant increased rate of bleeding and with
continued prevention of thromboembolism. For patients at high
thromboembolic risk, continued warfarin therapy should be
favored over heparin bridging, which increases bleeding, device
pocket hematoma, and health care costs. Presently, the use of
DOACs is commonly halted prior to insertion, but new evidence is
eagerly awaited to evaluate the risk to beneﬁt ratio of their con-
tinuation peri-operatively. The predictability and speed of their
waning effect is an advantage and the forthcoming availability of
speciﬁc- and complete-reversal agents may relieve concerns about
the management of potential bleeding complications. Combina-
tion antithrombotic therapy at the time of CIED should be avoided
when possible (e.g. in the absence of recent stent), with temporary
interruption of antiplatelet agents for patients on continued OAC.gement of antiplatelets [39].
Table 1
Peri-procedural (PM/ICD) management of antiplatelets—guideline recommendations.
ACCP 2012a [30] ACC/AHA 2014a [60] CCS 2012a [61] ESC/ESA 2014a,b [62] EHRA 2015a [39]
Aspirin Continue aspirin given
low-risk procedure
Continue aspirin given
low-risk procedure
N/A Continue aspirin given
low-risk procedure
Continue aspirin
DAPT- BMS Continue DAPT if o6
weeks post-insertion
Continue DAPT if o30 days
post-insertion
Minimum of 1-month
duration of DAPT
Minimum of 1-month
duration of DAPT
Minimum of 1-month duration of DAPT
DAPT- DES Continue DAPT if o6
months post-insertion
Continue DAPT if o12
months post-insertion
Minimum 3-month
duration of DAPT
Minimum 6-month dura-
tion of DAPT
Minimum 6-month duration of DAPT (3
months if new-generation DES)
Abbreviations: ACCP, American College of Chest Physicians; ACC/AHA, American College of Cardiology/American Heart Association; CCS, Canadian Cardiovascular Society;
ESC/ESA, European Society of Cardiology; DAPT, Dual Antiplatelet Therapy; BMS, Bare Metal Stent; DES, Drug Eluting Stent; N/A, Not Available.
a All guidelines recommend a delay in procedure if possible.
b ESC/ESA recommends at least 12 months of DAPT after ACS.
A. AlTurki et al. / Journal of Arrhythmia 32 (2016) 163–169168Funding
Dr. Essebag is the recipient of a Clinician Scientist award from
the Canadian Institutes of Health Research (CIHR).Conﬂict of interest
All authors declare no conﬂict of interest related to this study.References
[1] Lip GY. Stroke in atrial ﬁbrillation: epidemiology and thromboprophylaxis. J
Thromb Haemost 2011;9(Suppl 1):344–51.
[2] Falk RH. Atrial ﬁbrillation. N Engl J Med 2001;344:1067–78.
[3] Wipf JE, Lipsky BA. Atrial ﬁbrillation. Thromboembolic risk and indications for
anticoagulation. Arch Int Med 1990;150:1598–603.
[4] Menke J, Luthje L, Kastrup A, et al. Thromboembolism in atrial ﬁbrillation. Am
J Cardiol 2010;105:502–10.
[5] European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm
AJ, et al. Guidelines for the management of atrial ﬁbrillation: the Task Force
for the Management of Atrial Fibrillation of the European Society of Cardiology
(ESC). Eur Heart J 2010;31:2369–429.
[6] Steinberg BA, Piccini JP. Anticoagulation in atrial ﬁbrillation. Br Med J
2014;348:g2116.
[7] Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and
outcomes in patients with atrial ﬁbrillation: a systematic review and metaa-
nalysis. Chest 2004;126:1938–45.
[8] Gutierrez C, Blanchard DG. Atrial ﬁbrillation: diagnosis and treatment. Am
Fam Phys 2011;83:61–8.
[9] Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants
and antiplatelet drugs. Circulation 2007;116:305–15.
[10] Birnie DH, Healey JS, Wells GA, et al. Pacemaker or deﬁbrillator surgery
without interruption of anticoagulation. New Engl J Med 2013;368:2084–93.
[11] Samardhi H, Santos M, Denman R, et al. Current management of atrial
ﬁbrillation. Aust Prescr 2011;34:100–4.
[12] Mallouppas M, Vassiliou V. Anticoagulation for atrial ﬁbrillation: Is this the
end of warfarin? Not just yet J Angiol 2013;2013:1–7.
[13] January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the man-
agement of patients with atrial ﬁbrillation: executive summary. J Am Coll
Cardiol 2014;64:2246–80.
[14] Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial ﬁbrillation: Incidence,
prevalence, and prediction of stroke using the Congestive heart failure, hyper-
tension, age 475, diabetes mellitus, and prior Stroke or transient ischemic
attack (CHADS2) risk stratiﬁcation scheme. Am Heart J 2008;156:57–64.
[15] Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classiﬁcation
schemes for predicting stroke: results from the National Registry of Atrial
Fibrillation. J Am Med Assoc 2001;285:2864–70.
[16] Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial
ﬁbrillation for anticoagulation: stroke risk stratiﬁcation in patients taking
aspirin. Circulation 2004;110:2287–92.
[17] Lip GY, Nieuwlaat R, Pisters R, et al. Reﬁning clinical risk stratiﬁcation for
predicting stroke and thromboembolism in atrial ﬁbrillation using a novel risk
factor-based approach: the euro heart survey on atrial ﬁbrillation. Chest
2010;137:263–72.
[18] Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratiﬁcation schemes
for predicting stroke and thromboembolism in patients with atrial ﬁbrillation:
nationwide cohort study. Br Med J 2011;342:d124.
[19] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED)
to assess 1-year risk of major bleeding in patients with atrial ﬁbrillation: the
Euro Heart Survey. Chest 2010;138:1093–100.[20] Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin.
Understanding the dose-effect relationship. Clin Pharmacokin 1986;11:483–504.
[21] Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke pre-
vention in an elderly community population with atrial ﬁbrillation (the Bir-
mingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a rando-
mised controlled trial. Lancet 2007;370:493–503.
[22] Wysowski DK, Nourjah P, et al. Bleeding complications with warfarin use: a
prevalent adverse effect resulting in regulatory action. Arch Int Med
2007;167:1414–9.
[23] Molteni M, Cimminiello C. Warfarin and atrial ﬁbrillation: from ideal to real
the warfarin affaire. Thromb J 2014;12:5.
[24] Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients
with warfarin-associated coagulopathy. J Am Coll Cardiol 2006;47:804–8.
[25] Sticherling C, Marin F, Birnie D, et al. Antithrombotic management in patients
undergoing electrophysiological procedures: a European Heart Rhythm
Association (EHRA) position document endorsed by the ESC Working Group
Thrombosis, Heart Rhythm Society (HRS), and Asia Paciﬁc Heart Rhythm
Society (APHRS). Europace 2015;17:1197–214.
[26] Ogawa S, Aonuma K, Tse H-F, et al. The APHRS's 2013 statement on antith-
rombotic therapy of patients with nonvalvular atrial ﬁbrillation. J Arrhythm
2013;29:190–200.
[27] Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications
and practical considerations. Eur J Clin Pharm 2013;69:1617–33.
[28] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in
patients with atrial ﬁbrillation. N Engl J Med 2009;361:1139–51.
[29] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-
valvular atrial ﬁbrillation. N Engl J Med 2011;365:883–91.
[30] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in
patients with atrial ﬁbrillation. N Engl J Med 2011;365:981–92.
[31] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in
patients with atrial ﬁbrillation. N Engl J Med 2013;369:2093–104.
[32] Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm
Association Practical Guide on the use of non-vitamin K antagonist antic-
oagulants in patients with non-valvular atrial ﬁbrillation. Europace
2015;17:1467–507.
[33] Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly
adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc
2014;62:857–64.
[34] Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of
antithrombotic therapy: antithrombotic therapy and prevention of thrombo-
sis, 9th ed: American College of Chest Physicians evidence-based clinical
practice guidelines. Chest 2012;141:e326S–50S.
[35] Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and
practice-based evidence in periprocedural anticoagulation. Circulation
2012;126:1573–6.
[36] Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients
receiving vitamin K antagonists: systematic review and meta-analysis of
bleeding and thromboembolic rates. Circulation 2012;126:1630–9.
[37] Bernard ML, Shotwell M, Nietert PJ, et al. Meta-analysis of bleeding compli-
cations associated with cardiac rhythm device implantation. Circ Arrhythm
Electrophysiol 2012;5:468–74.
[38] Proietti R, Porto I, Levi M, et al. Risk of pocket hematoma in patients on
chronic anticoagulation with warfarin undergoing electrophysiological device
implantation: a comparison of different peri-operative management strate-
gies. Eur Rev Med Pharm Sci 2015;19:1461–79.
[39] Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker
or implantable cardioverter–deﬁbrillator generator replacements and upgrade
procedures: results from the REPLACE registry. Circulation 2010;122:1553–61.
[40] Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging antic-
oagulation in patients with atrial ﬁbrillation. N Engl J Med 2015;373(9):823–33.
[41] Sant'anna RT, Leiria TL, Nascimento T, et al. Meta-analysis of continuous oral
anticoagulants versus heparin bridging in patients undergoing CIED surgery:
reappraisal after the BRUISE study. Pacing Clin Electrophysiol 2015;38:417–23.
[42] Coyle D, Coyle K, Essebag V, et al. Cost effectiveness of continued-warfarin
versus heparin-bridging therapy during pacemaker and deﬁbrillator surgery. J
Am Coll Cardiol 2015;65:957–9.
A. AlTurki et al. / Journal of Arrhythmia 32 (2016) 163–169 169[43] Spinler SA, Shaﬁr V. New oral anticoagulants for atrial ﬁbrillation. Circulation
2012;126:133–7.
[44] Nascimento T, Birnie DH, Healey JS, et al. Managing novel oral anticoagulants
in patients with atrial ﬁbrillation undergoing device surgery: Canadian survey.
Can J Cardiol 2014;30:231–6.
[45] Gladstone DJ, Geerts WH, Douketis J, et al. How to monitor patients receiving
direct oral anticoagulants for stroke prevention in atrial ﬁbrillation: a practice
tool endorsed by thrombosis Canada, the Canadian Stroke Consortium, the
Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovas-
cular Society. Ann Int Med 2015;163:382–5.
[46] Ottawa Heart Institute Research Corporation. Strategy of Continued Versus
Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients
With Moderate to High Risk of Arterial Thromboembolic Events. Bethesda (MD):
National Library of Medicine (US) 2000 (cited 2015 Jul 18). (Available from:
〈〈http://clinicaltrials.gov/show/NCT01675076〉〉 NLM Identiﬁer: NCT01675076).
[47] Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulants in the
perioperative and intensive care unit setting. Anesthesiology 2013;118:1466–74.
[48] Birnie DH, Healey JS, Essebag V. Management of anticoagulation around
pacemaker and deﬁbrillator surgery. Circulation 2014;129:2062–5.
[49] Jennings JM, Robichaux R, McElderry HT, et al. Cardiovascular implantable
electronic device implantation with uninterrupted dabigatran: comparison to
uninterrupted warfarin. J Cardiovasc Electrophysiol 2013;24:1125–9.
[50] Rowley CP, Bernard ML, Brabham WW, et al. Safety of continuous antic-
oagulation with dabigatran during implantation of cardiac rhythm devices.
Am J Cardiol 2013;111:1165–8.
[51] Garcia DA, Crowther MA. Reversal of warfarin: case-based practice recom-
mendations. Circulation 2012;125:2944–7.
[52] Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to
normalize the international normalized ratio prior to surgery in patients who
require temporary interruption of warfarin. J Thromb Thrombolysis 2007;24:93–7.
[53] Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the
international normalized ratio more rapidly than subcutaneous vitamin K inthe treatment of warfarin-associated coagulopathy. A randomized, controlled
trial. Ann Intern Med 2002;137:251–4.
[54] Lauw MN, Coppens M, Eikelboom JW. Recent advances in antidotes for direct
oral anticoagulants: their arrival is imminent. Can J Cardiol 2014;30:381–4.
[55] Siegal DM, Crowther MA. Acute management of bleeding in patients on novel
oral anticoagulants. Eur Heart J 2013;34:489b–98b.
[56] Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran
removal in the treatment of acute bleeding: a single center experience. Clin J
Am Soc Nephrol 2013;8:1533–9.
[57] Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding
complications in patients undergoing anticoagulant therapy: focus on new
anticoagulant agents. Blood 2008;111:4871–9.
[58] Pollack Jr. CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran
reversal. N Engl J Med 2015;373:511–20.
[59] Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of
factor Xa inhibitor activity. N Engl J Med 2015 [Epub ahead of print].
[60] Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin
"bridging" signiﬁcantly increase the risk of bleeding complications after
pacemaker or implantable cardioverter–deﬁbrillator device implantation. J
Am Coll Cardiol 2010;55:2376–82.
[61] Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and
cardiac events after percutaneous coronary intervention (PARIS): 2 year
results from a prospective observational study. Lancet 2013;382:1714–22.
[62] Korantzopoulos P, Letsas KP, Liu T, et al. Anticoagulation and antiplatelet
therapy in implantation of electrophysiological devices. Europace
2011;13:1669–80.
[63] Godier A, Taylor G, Gaussem P. Inefﬁcacy of platelet transfusion to reverse
ticagrelor. N Engl J Med 2015;372(196):7.
